Details of the Drug

General Information of Drug (ID: DMI2YU1)

Drug Name

GSK2336805

Synonyms

GSK-2336805

Indication

Disease Entry	ICD 11	Status	REF
Hepatitis C virus infection	1E51.1	Phase 2	[1]
------------------------------------------------------------------------------------

Structure

3D MOL is unavailable

2D MOL

Chemical Identifiers

Formula: C42H52N8O8
Canonical SMILES: CC(C)C(C(=O)N1CCCC1C2=NC=C(N2)C3=CC=C(C=C3)C4=CC=C(C=C4)C5=CN=C(N5)C6CC7(CN6C(=O)C(C(C)C)NC(=O)OC)OCCO7)NC(=O)OC
InChI: 1S/C42H52N8O8/c1-24(2)34(47-40(53)55-5)38(51)49-17-7-8-32(49)36-43-21-30(45-36)28-13-9-26(10-14-28)27-11-15-29(16-12-27)31-22-44-37(46-31)33-20-42(57-18-19-58-42)23-50(33)39(52)35(25(3)4)48-41(54)56-6/h9-16,21-22,24-25,32-35H,7-8,17-20,23H2,1-6H3,(H,43,45)(H,44,46)(H,47,53)(H,48,54)/t32-,33-,34-,35-/m0/s1
InChIKey: YMCAVGXTSCNFDE-BBACVFHCSA-N

Cross-matching ID

References

1	ClinicalTrials.gov (NCT01439373) Safety, Antiviral Activity, and Pharmacokinetics of GSK2336805 With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects. U.S. National Institutes of Health.